UTMD Q2 net income up 161%, EPS $0.937; revenue $12.6M (+43%); guides FY EBITDA ~$25M

UTAH MEDICAL PRODUCTS INC

2021-Q2 EPS reported $1.76 revenue$23,568,000

Q2 revenue $12.6M (+43% YoY); domestic +46%, OUS +40%; constant-currency sales +40%.
GAAP EPS $0.937 (up 161%); non-GAAP (ex-UK DTL) EPS $1.044 (up 148%).
Operating income $4.765M (+141%); gross margin 61.8% vs 56.3% a year ago.
Management likely expects FY2021 adjusted EBITDA of ~$25M; TTM EBITDA $24.0M.
Cash $59.5M, no debt; quarterly dividend $0.285/share (up from $0.280).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.